Final program and Abstracts€¦ · Page 4 CIEMAT 24-25 November 2016 -Industry matching event on superconductivity for ContentsAcademia accelerators for medical applications

Com

mittee

25 N

ov

Notes

Gen

eral Info

F

orew

ord

S

pon

sors

24 N

ov

Academia-Industry Matching

Event on Superconductivity for

Accelerators for Medical

Applications

Centro de Investigaciones Energéticas Medioambientales y Tecnológicas,

CIEMAT- Madrid

Thursday 24 November 2016 – Friday 25 November 2016

Final program and

Abstracts

Website: https://indico.cern.ch/e/SC4MedAccelerators2016

Page 1 CIEMAT 24-25 November 2016



Academia-Industry matching event on superconductivity for

accelerators for medical applications

Contents

Contents

1. Foreword .................................................................................................... 5

2. Committee .................................................................................................. 6

2.1 Organising Committee ................................................................................ 6

2.2 Scientific Committee ................................................................................... 6

3. General Information ................................................................................. 7

3.1 Congress Venue .......................................................................................... 7

3.2 Internet ........................................................................................................ 7

3.3 Registration desk and bags pick up ............................................................. 7

3.4 Certificate of attendance.............................................................................. 7

3.5 Coffees ........................................................................................................ 7

3.6 reception cocktail ........................................................................................ 7

3.7 Banquet dinner ............................................................................................ 8

3.8 Exhibition .................................................................................................... 8

3.9 Non-liability ................................................................................................ 8

3.10 Program Schedule ..................................................................................... 9

3.10.1 November 24, Thursday ............................................................................. 9

3.10.2 November 25, Friday................................................................................ 10

4. Introductory session ................................................................................ 11

4.1 Welcome address ...................................................................................... 11

4.2 Accelerators for medical applications ....................................................... 12

4.3 Overview of Superconductivity and its applications ................................. 13

4.4 Superconducting technology for next generation accelerators .................. 15

5. Radioisotope production session ............................................................ 17

5.1 Radiopharmaceutical production process .................................................. 17

5.2 Compact accelerators for pet production: AMIT project .......................... 19

5.3 Compact accelerators for pet production: LOTUS project ........................ 20

5.4 Compact high cyclotrons for n13 amonia and fdg .................................... 21

5.5 PET center for low patient traffic and the rf system for its cyclotron ....... 23

5.6 CERN MEDICIS and MEDICIS-PROMED: Novel radioisotope

production for medical applications ......................................................... 24

5.7 Medical imaging........................................................................................ 26


Contents Academia-Industry matching event on superconductivity for


6. Particle therapy session .......................................................................... 27

6.1 Developing a modern, high-quality proton therapy medical device using a

compact superconducting synchrocyclotron ............................................ 27

6.2 Superconducting medical accelerators at IBA .......................................... 29

6.3 Superconducting magnets for Ultra-Light and magnetically shielded,

compact cyclotrons for medical applications ........................................... 30

6.4 Modern injector linac concepts for hadrontherapy .................................... 32

6.5 Superconductivity in cyclinacs for ion beam therapy ............................... 33

7. Gantries session ....................................................................................... 34

7.1 Introduction to gantries and comparison of gantry design ........................ 34

7.2 Advantages and challenges of sc magnets in gantries ............................... 35

7.3 Superconducting magnets for medical applications at psi ......................... 36

7.4 SC gantry at nirs and new developments in sc magnets for gantries &

synchrotrons ............................................................................................. 37

7.5 Cryogenic design and colling methods for rotating sc magnets ................ 38

7.6 Cryogen free cryogenic cooling system for rotating superconducting

magnets in medical accelerators ............................................................... 39

8. Sponsors ................................................................................................... 41




Foreword

Fo

reword

1. FOREWORD

In our daily life, superconducting accelerators can be used to produce short-life

radionuclides for making diagnoses, or to accelerate protons and ion beams to treat

tumours. Currently, superconductivity has become a key technology for particle

accelerators, boosting their performances and reducing their sizes.

Experienced researchers and leading companies in the field of superconductivity will

gather at CIEMAT to explore the technical challenges emerging from the design of

new particle accelerator trying to match them with state-of-the-art medical

solutions.

The scope of this workshop is to bring together experts from different fields like

superconducting magnets, cryogenics or medical physics with representatives from

industry to discuss and review the current status, the requirements and the challenges

of the technology and its applications in this field. The workshop should foster

interactions amongst people in different laboratories, institutions and industries.

The programme of the Event focuses on three main areas of expertise:

Radioisotope production

Particle therapy

Gantries

Scientific and industrial presentations, as well as Q&A sessions will be interleaved

to maximize knowledge exchange opportunities between the attendants to the event.


Com

mit

tee



Committee

2. COMMITTEE

2.1 ORGANISING COMMITTEE

Susana Falcón, CIEMAT

Luis García-Tabarés Rodríguez, CIEMAT

Diego Obradors, CIEMAT

Concepción Oliver, CIEMAT

Manuela Cirilli, CERN

Jean-Marie Le Goff, CERN

Giovanni Porcellana, CERN,

Antonio de Valladares Pacheco, CERN

Anna Mccabe, ESP CENTRAL

Álvaro Bort, EEN

2.2 SCIENTIFIC COMMITTEE

Luis García-Tabarés Rodríguez, CIEMAT

Diego Obradors, CIEMAT

Concepción Oliver, CIEMAT

Jean-Marie Le Goff, CERN

Martina Bauer, GSI

Tobias Engert, GSI

Mike Seidel, PSI

Rob Edgecock, STFC




General Information

Gen

eral Info

3. GENERAL INFORMATION

3.1 CONGRESS VENUE

The congress venue is in:

Centro de Investigaciones, Energía, Medioambiente y Tecnología, CIEMAT

Auditorium, Edificio 1

Avenida Complutense, 40

28040, Madrid, Spain

3.2 INTERNET

Wi-fi internet connection is provided in the venue. Please, note that it is a

complimentary and a basic service:

Network: Visitor

User: AIME

Password: SCMED2016

3.3 REGISTRATION DESK AND BAGS PICK UP

The registration desk is located in the main hall of the auditorium.

Opening hours:

Thursday, 24 November: 10:30 h – 16:00 h

All registrant must go to the conference registration desk in the main hall.

Each registrant will receive one copy of the final program and one

delegate bag.

3.4 CERTIFICATE OF ATTENDANCE

All certificates will be sent by email after the conference.

3.5 COFFEES

Coffees during breaks will be served in the exhibition area in the second

floor of the auditorium building. Please refer to the schedule to the

schedule for dates and times.

3.6 RECEPTION COCKTAIL

Date: Thursday, 24th from 11:30 to 13:00


Gen

eral

In

fo



General Information

Location:Exhibition hall

Admision: All registered delegates

3.7 BANQUET DINNER

Date: Thursday, 24th at 20:30

Place: Real Café Bernabéu

Location: Estado Santiago Bernabéu, Avenida de Concha Espina, 1,

puerta 30, 28036, Madrid. +34 914583667

Admision: All registered delegates

Transportation: There will be a bus shuttle starting at 19:00 from

CIEMAT to Estadio Santiago Bernabéu.

3.8 EXHIBITION

Booths are located in the exhibition area, (second floor of the auditorium

building). Attendees are encouraged to spend time visiting booths and

interacting with the exhibitors.

3.9 NON-LIABILITY

The organisation has the right, for any reason beyond their control, to

modify or cancel, without prior notice, the sessions or any of the

arrangements, timetables, plans or other items. The organisers will not

responsible for any loss, damage, expenditure or inconvenience caused to

participants, and their belongings, either during or as a result of the

conference.




General Information

Gen

eral Info

3.10 PROGRAM SCHEDULE

3.10.1 NOVEMBER 24, THURSDAY

11:30 - 13:00

13:00 - 13:30 Welcome Address

13:30 - 13:50 Accelerators for medical applications

13:50 - 14:10 Overview of superconductivity and its applications

14:10 - 14:30

Superconducting technologies for the next generation of

accelerators devices

14:30 - 14:50

14:50 - 15:20

15:20 - 15:40 Radiopharmaceutical production process

15:40 - 16:00 Compact accelerators for PET production: AMIT Project

16:00 - 16:20 Compact accelerators for PET production: LOTUS Project

16:20 - 16:40 Compact high field cyclotrons for N13 Amonia and FDG

16:40 - 17:10

17:10 - 17:30

PET center for low patient traffic and the RF systems for

its cyclotron

17:30 - 17:50

CERN MEDICIS and MEDICIS-PROMED: Novel radioisotope

production for medical applications

17:50 - 18:10 Medical imagining

18:10 - 18:30

Question and answer session

Radioisotope production session Chairman: Francisco Alves, ICNAS

Teresa Puig, ICMAB

Lucio Rossi, CERN

Cofee and networking break

Introductory session Chairman: Luis García-Tabarés, CIEMAT

Ramón Gavela, CIEMAT: Fernando Ballestero, MINECO

Michael Schillo, Varian Medical

Reception Cocktail

Gregory Sharkov, NIIFTA

Simon Stegemann, KU Leuven


Fernado Berdascas, Beta Pharma Technologies

Javier Munilla, CIEMAT

Raymond Pommet, PMB ALCEN

Timothy Antaya, Antaya Science & Technology

Cofee and networking break

Jordi Llop, CIC BiomaGUNE


Gen

eral

In

fo



General Information

3.10.2 NOVEMBER 25, FRIDAY

08:30 - 08:50

Developing a modern, high-quality proton medical device

using a compact superconducting synchrocyclotron

08:50 - 09:10 Superconducting medical accelerators at IBA

09:10 - 09:30

Superconducting magnets fo Ultra-Light and magnetically

shielded, compact cyclotrons for medical applications

09:30 - 10:00

10:00 - 10:20 Modern injector linac concepts for hadrontherapy

10:20 - 10:40 Superconductivity in cyclinacs for ion beam therapy Adiano Garona, TERA Foundation

10:40 - 11:00

11:00 - 11:20 Introduction to gantries and comparison of gantry design Marco Pullia, CNAO. Frank Ebskamp, Danfysik

11:20 - 11:50

11:50 - 12:10 Advantages and challenges of SC magnets in gantries

12:10 - 12:30 Superconducting magnets for medical applications at PSI

12:30 - 12:50

SC gantry at NIRS and new developments in SC magnets for

gantries & synchrotrons

12:50 - 13:10 Cryogenic design ad colling methods for rotating SC magnets

13:10 - 13:30

Cryogen free cryogenic cooling system for rotating

superconducting magnets in medical accelerators

13:30 - 13:50

Santiago Sanz, TECNALIA

Cofee and networking break break

Bertrand Baudouy, CEA Saclay


Particle therapy session Chairman: Luciano Calabrett, INFN

Townsend Zwart, MEVION Medical Systems

Bernhard Schlitt, GSI

Wiel Kleeven, IBA

Joseph V. Minervini, MIT


Gantry session Chairman: Jürgen Duppich, PSI

Alexander Gerbershagen, PSI

Ciro Calzolaio, PSI

Yoshiyuki Iwata, NIRS

Cofee and networking break break




Introductory Session

24 N

ov

4. INTRODUCTORY SESSION

4.1 WELCOME ADDRESS

R. Gavela González

Director

Centro de Investigaciones, Energía, Medioambiente y

Tecnología, CIEMAT , Madrid, Spain

F. Ballestero Díaz

Subdirector General de Relacciones Internacionales

Secretaría de Estado de I+D+i del Ministerio de

Economía y Competitividad, Madrid, Spain


24 N

ov




4.2 ACCELERATORS FOR MEDICAL APPLICATIONS

Corresponding Authors: M. Schillo

Varian Medical Systems

Particle Therapy GmbH, Troisdorf, Germany

This talk will mainly focus on superconducting cyclotrons from a medical

device manufacturer's perspective. First, a short rationale of and an

introduction to particle therapy are given. The major requirements for a

particle therapy accelerator will be deduced from the treatment process.

Based on that a comparison of various accelerator types for the use in an

industrial medical device is made.

In the second part, a short history of superconducting cyclotrons up to the

current status will be presented, concluding with an outlook on future

superconducting cyclotrons.

Lecturer biography: M. Schillo

Michael Schillo is senior manager of the Advanced Development Department

at Varian Medical Systems Particle Therapy in Troisdorf, Germany.

He received his PhD in Physics at the University of Bonn for advanced beam

diagnostics for an electron storage ring. In 1992 he joined the accelerator

department at Siemens KWU, which, following a management buyout,

became ACCEL Instruments GmbH. Subsequently he worked as a technical

project manager on various development projects for superconducting

magnets and accelerator components. In 2001 he was assigned head of the

development team at ACCEL for the development of a superconducting

compact 250MeV cyclotron for the Paul Scherrer Institute, Switzerland. In

2002 with the start of the development for the Rinecker Proton Therapy

Center in Munich he took over the task to lead the development of a complete

medical proton therapy facility. After acquisition of ACCEL by Varian

Medical Systems he coordinated as engineering manager the transition of a

small business project team to a medical device manufacturer engineering

department. He is now dedicating his skills and experience to the future

advancement of Proton Therapy.





24 N

ov

4.3 OVERVIEW OF SUPERCONDUCTIVITY AND ITS

APPLICATIONS

Corresponding Authors: T. Puig

Consejo Superior de Investigaciones Científicas,

CSIC

Institut de Ciencia de Materials de Barcelona,

Barcelona, Spain

Superconductivity is a quantum phenomenon discovered more than 100 years

ago with important implications in our lives even though we do not usually

realise it. This exotic phenomenon is able to detect the smallest magnetic

fields and generate the largest magnetic fields in the world. In the first case,

SQUIDs (superconducting quantum interference devices) were developed as

the most sensitive magnetic field detectors and nowadays a large area of

superconducting RSFQ logics and q-bits is steady progressing in the field of

quantum computing. In the second case, high field magnets have been

extensibly developed making possible high energy accelerators and magnetic

resonance (NMR and MRI). Since the discovery of high temperature

superconductors (HTS), energy applications appeared as possible thanks to

the liquid nitrogen operation temperature. However, the nature of the HTS

materials, being ceramic instead of metallic, has strongly slowed down their

real application implementation. Thanks to one of the ever largest constant

efforts in material science during the last 20 years, nowadays these HTS

materials are industrially produced as flexible long length conductors and a

large number of different device prototypes have been demonstrated.

Recently, the scientific community has also realized that some of these HTS

materials are the highest field conductors available at helium temperatures,

thus opening new opportunities also in the area of ultrahigh magnetic fields

for high energy accelerators, magnetic resonance and fusion. In this

presentation, I will revise the most relevant properties of Superconductivity,

the superconducting materials opportunities for the different operation

temperatures and the situation of superconducting applications in the

different sectors (energy, medicine, fusion,..).

Lecturer biography: T. Puig

She received the B.S in Physics (1989) and the Ph.D. in Physics (1994) from

Universitat Autònoma de Barcelona, Spain. After pre- and postdoctoral

positions (46 months) at Royal Institute of Technology of Stockholm


24 N

ov




(Sweden), Trinity College Dublin (Ireland), Univesität Regensburg

(Germany) and Katholieke Universiteit Leuven (Belgium), she became

tenured scientist at Barcelona Materials Science Institute (ICMAB-CSIC) in

2000, and in 2010 she was appointed Full Professor. Since 2008 she is Head

of the Superconducting Materials and large scale nanostructures Department

of ICMAB. Her scientific interest includes functional oxides and

superconducting materials, preparation and understanding of their physical

properties, and materials integration in devices. She has been Editorial

Executive Board member of Superconducting Science and Technology (IOP-

SUST) from 2009 till 2014, and since 2005 was at the Advisory Board. She

is Board member of European Society for Applied Superconductivity (ESAS)

since 2007 and Associated Editor of the Superconducting News Forum. She

is co-founder of the spin-off company OXOLUTIA created from the ICMAB

group. She has been principle investigator of several national and EU

projects. She has published more than 275 peer review papers (with 3500

citations and h=29), holds 11 patents and has supervised 16 PhD Thesis.

She’s organized several international conferences including two MRS-spring

symposiums. She has received several awards in the area of applied

superconductivity (Duran Farrell award for Technology Research in

superconducting fault current limiters, 2002; Novare-Endesa for R+D+i in

Energy with the superconducting cable, 2007; and ITEK Award for Ink Jet

Printing for functional ceramic coatings, 2012) and this year “Barcelona City

prize to Experimental science and technology 2015”. In 2015 too, she was

awarded with an ERC- Advanced Grant in the area of superconducting

nanocomposite coated conductors using fast growth processing for ultrahigh

magnetic fields generation.





24 N

ov

4.4 SUPERCONDUCTING TECHNOLOGY FOR NEXT

GENERATION ACCELERATORS

Corresponding Authors: L. Rossi

European Organisation for Nuclear Research,

CERN

Technology Department, Geneva, Switzerland

Meanwhile LHC is exploring the energy frontier of particle physics, CERN

with CIEMAT and other numerous Laboratories and Institutions is

developing new technologies for next generation colliders. The High

Luminosity LHC is now near construction with Superconducting magnet

capable of 12 T field, made with advanced Nb3Sn technology, while for FCC

a new R&D phase just started to be able to reach magnetic field of 15-16

tesla. Even the 20 T range seems not impossible thanks to novel HTS based

magnets. In addition, superconducting cavities (SRF) are greatly advancing,

with more efficient and high gradient RF systems, and developing new

devices like the HiLumi Lhc crab cavities that are able to deflect or rotate

each single bunch. The talk will illustrate the advance in all these

technologies, including high current (> 100 kA) SC links, and the possible

strong impact on the future of medical accelerators.

Lecturer biography: L. Rossi

Lucio Rossi became doctor in Physics in 1980 with a thesis in Plasma

Physics; in 1992 became Professor of Experimental Physics at the University

of Milan. He worked on design and construction of the first European

Superconducting Cyclotron and then developed new superconducting

materials for accelerators (high current density Nb3Sn and high temperature

superconductors – HTS). Meanwhile he was responsible of the first LHC

dipole magnet prototype for CERN (tested in 1994, instrumental for project

approval) and of the first large Superconducting Toroidal coils of ATLS

experiment at LHC(1996-2001). In 2001 he joined CERN to lead the

construction of Magnets & Superconductors for the LHC Project, the largest

scientific instruments with a budget of more than 1.5 billion CHF. From 2010,

he is the leader of the High Luminosity LHC, an international project with a

budget of about 1 billion CHF that, through development of new cutting

technologies, aims at a five-fold increase of the luminosity of the LHC at the

horizon 2025. He is Project coordinator of the European project FP7-HiLumi

LHC (2011-2015) and the coordinator of FP7-Eucard2-WP10 (2013-2016),


24 N

ov




devoted to qualify novel HTS materials for future accelerators, like –but not

only - the Future Circular Collider (FCC) Project.

He has been Chair of Int. Conf. on Magnet Technology 2005 (MT-19), held

in Genova 18-23 Sept, and is member of the MT International Board since

2000. L. Rossi has received the IEEE Council of SuperConductivity Award

for sustained scientific accomplishment in applied superconductivity in 2007,

and has been nominated IEEE-CSC Distinguished Lecture for

Superconductivity for 2013-14. In 2013, he has been elevated to the grade of

IEEE Fellow. Elected member of the ESAS board (European Society for

Applies Superconductivity) for 2011-17, L. Rossi is chair of the European

Conference on Applied Superconductivity EUCAS-2017 that will be held in

Geneva.

He is very active in public outreach: he is founding member from 1985 of

“Euresis”, an association for the promotion of scientific culture established

in Milan, organizing public Science Exposition, and he gives a dozen of talks

per year to public on science and on relation between Science and

Technology, Certainty and Truth.




Radioisotope Production Session

24 N

ov

5. RADIOISOTOPE PRODUCTION SESSION

5.1 RADIOPHARMACEUTICAL PRODUCTION PROCESS

Corresponding Authors: F. Berdascas Julián, C. García-Tabarés

Valdivieso

Beta Pharma Technologies, Madrid, Spain.

Radioisotope production is the first step in radiopharmaceuticals production

workflow. In an accelerator based radiopharmaceuticals production facility,

the impact of the radiopharmacy equipment on its global footprint is

sometimes as important as the accelerator itself. Accelerator design, size and

energy has a direct impact on the global installation scale: power electronics,

shielding, bunker, etc. Superconducting cyclotrons reduce considerably the

footprint of this part of the installation if compared to traditional resistive ones

allowing their installation in small hospitals or research centres. Apart from

the cyclotron it is needed to develop new targetry adapted to this new

production scale model for a cost effective radioisotope production. To

achieve a compact radiopharmaceutical production system, we need to scale

also the rest of the radiopharmacy equipment: synthesis modules, hot cells,

dose calibrators, dose dispensers and quality control equipment. Recent

developments include microfluidics based synthesis modules and compact

quality control solution. Once all this technological development will match

this new radiopharmaceuticals production model, the next challenge will be

to make it compliant with nuclear and pharmaceutical regulations which have

been created based on traditional radiopharmaceutical production

Lecturer biography: F. Berdascas

Engineering Manager and co-founder of Beta Pharma Technologies. Prior to

founding Beta Pharma Technologies in 2014, He worked as Cyclotron

Engineer for Advanced Accelerator Applications, a European leader in the

production and commercialization of molecular nuclear diagnostic

radiopharmaceuticals for PET and SPECT, and served as Chief Technical

Officer and Chief Operating Officer for Instituto Tecnológico PET, one of the

PET producer and distributor leaders in Spain.

He hold a Master’s Degree in Industrial Engineering from Universidad de

Zaragoza and a Master’s Degree in Mechanical Engineering from Université

de Technologie de Compiègne. He has attended several topic-specific


24 N

ov




advanced service trainings for different medical cyclotrons and has extensive

experience in PET radiopharmaceutical production





24 N

ov

5.2 COMPACT ACCELERATORS FOR PET PRODUCTION:

AMIT PROJECT

Corresponding Authors: J. Munilla on behalf of Unidad de Ingeniería

eléctrica, CIEMAT

Centro de Investigaciones, Energía,

Medioambiente y Tecnología, CIEMAT.

Unidad de Ingeniería Eléctrica, Madrid, Spain.

The delivery of FDG from large central production centres has demonstrated

to be a cost-effective solution for populated areas, but the interest on other

tracers has raised expectations that cannot be satisfied by using that concept.

A new production method aimed to provide in-situ single doses of 18F and,

fundamentally, 11C-radiotracers, would satisfy the requisites for non-

standard PET demands. In this context, the project AMIT has been launched

to develop, among other things, a new method for delivering single-doses of

in-situ produced radiotracers, based on a compact cyclotron.

The project proposes a compact superconducting design, based on a

Lawrence-type machine. It will be able to produce low to moderate rates of

dose-on-demand 11C and 18F. This will be achieved by accelerating 10

microamperes of H- up to 8.5 MeV. Such a simple concept of machine,

combined with a superconducting Helmholtz magnet with warm iron allows

to develop a cost-effective machine with additional features like its high

thermal efficiency (magnet can be cooled with just one commercial

cryocooler and a closed helium circuit) and a small footprint which ends on a

compact system that could be of interest to three types of potential customers:

Small remote hospitals, hospitals engaged with personalized medicine and

research institutions.

The presentation will describe the main aspects of the superconducting

technology associated to this cyclotron.

Lecturer biography: J. Munilla

Javier Munilla is at Accelerator technology group at CIEMAT since 2008. He

is a physicist and mechanical engineer who is at this moment finishing his

PhD on the magnet design of the cyclotron for AMIT project. Some of the

topics of his interest include structural and thermal modeling, high precision

mechanics and material science. In this last topic he is working as collaborator

teacher for Comillas University since 2013


24 N

ov




5.3 COMPACT ACCELERATORS FOR PET PRODUCTION:

LOTUS PROJECT

Corresponding Authors: R. Pommet

PMB Alcen, Peynier, France.

Molecular imaging with Positron Emission Tomography (PET) is playing an

important role in patient care, medical research, and pharmaceutical

development. But limitations in short-lived positron emitters availability

restrict the use of new radiopharmaceuticals that therefore remains limited to

a small number of advanced research facilities. In order to enlarge the use of

molecular imaging for translational research and clinical diagnosis, we

designed an automated production system for PET radiopharmaceuticals on a

“dose-on-demand” basis.

The LOTUS project is a French industry/academic partnership project, leaded

by PMB (ALCEN Group), a designer and manufacturer of particle

accelerators, RF assemblies, and advanced mechanical designs. The two other

partners involved are the CEA, a technological research public organization,

and SigmaPhi, a designer and producer of magnetic systems.

The LOTUS system features a compact 12 MeV superconducting Helium-

free magnet cyclotron, with an external self-shielded beam and targetry

system, particularly suitable for the production of Carbon-11, Fluor-18 and

Gallium-68 radioisotopes. A microfluidic GMP automated synthesis platform

allows the radiolabeling of a wide range of biomarkers for PET molecular

imaging.

Lecturer biography: R. Pommet

Raymond Pommet is senior vice president Business Development Healthcare

at PMB (ALCEN Group), responsible for developing new medical device

business initiatives and strategic partnerships.

Raymond has an extensive academic and industry experience in innovation

management and technology transfer, having spent 35 years in contributing

to bridge academic innovation and the marketplace, both in

radiopharmaceuticals and biomedical technologies.

Prior joining PMB, Raymond held different positions in product

development, marketing and business development, international cooperation

programs and innovation management, in academic institution and public

research-funding agency, as well as biomedical industry.

Raymond holds a PhD in Medical nuclear physics from the University of

Lyon and an Executive MBA from HEC Business school.





24 N

ov

5.4 COMPACT HIGH CYCLOTRONS FOR N13 AMONIA AND

FDG

Corresponding Authors: TA. Antaya1, K. Cameron 2

1 Antaya Science and Technology, Hampton NH,

USA 2 Ionetix Corporation, San Francisco, USA

Over the past few years Mo-99m supply instability coupled with directives to

eliminate the production dependence on HEU, have stimulated a number of

new accelerator and reactor based concepts for the production of the

important tracer Tc-99m following the conventional M0-99m carrier

route. However, if one were to start from scratch today Tc-99m would not

likely be used. There is a better cardiac imaging agent with much higher

resolution images, significantly lower doses to patients and lower dwell times

in patients, and essentially no radioactive waste- N13 Ammonia. This ‘gold

standard’ for cardiac perfusion imaging has one limiting challenge- it’s short

~10 minute half-life, which nearly requires the isotope generator, in this case

a low energy proton cyclotron and a water target, to be co-located or at least

within a half-life or two of the PET camera. In this talk we will report on the

development of a portable high field superconducting cyclotron for the

production of unit dose N13 Ammonia in near proximity to the PET cameras,

now being commercialized by Ionetix. Switching from O18 depleted water to

O18 enriched water turns this N13 ammonia generator into a unit dose FDG

generator, which will also be discussed.

Lecturer biography: TA. Antaya

Dr. Timothy A Antaya - designer, inventor, scientist, pilot, has 3 decades of

technical experience and scientific leadership in research organizations and

companies involved in the development of large scale electromagnetic

devices for basic science and related commercial applications- medicine,

security and industry. He has more than 100 research publications, and has

participated in or led 8 superconducting cyclotron campaigns, developing

more than 25 patents in the field of superconducting cyclotrons and related

technologies. His research specialties include: compact superconducting

cyclotron design, circular particle accelerator beam dynamics theory and

simulation codes, ion sources and beam formation processes, electron

cyclotron resonance ion sources, low energy beam transport, electromagnetic

field design and analysis, coupled electromagnetic mechanical design, large

scale superconductivity, cryogenics, and accelerator physics education. He is


24 N

ov




a member of the American Physical Society, IEEE, New York Academy of

Science, The American Association for the Advancement of Science, the

Society for Science & the Public, Scientists Without Borders, and the

American Health Council. In addition in 2014 he founded the Antaya

Foundation for Science and Technology, where annually talented high school

students can get their first real exposure in the use of basic science to make

big steps in advanced technologies





24 N

ov

5.5 PET CENTER FOR LOW PATIENT TRAFFIC AND THE RF

SYSTEM FOR ITS CYCLOTRON

Corresponding Authors:G.B. Sharkov, T.V. Bondarenko, A.A.

Krasonov, S. Polikhov

Institute of Technical Physics and

Automation, NIITFA, Moscow, Russia

Two topics will be discussed in the presentation. Firstly, a new high power

efficient RF generator with outstanding availability has been developed,

tested and is commercially available. The system meets the customer

demands on compactness, usability, high reliability. Special modular

architecture allowed to design scalable solution for various frequencies,

output powers and duty cycles (up to CW). Control system of the generator

has features specially designed for PET cyclotrons. The architecture and tests

of 72 MHz 10 kW CW generator prototype are presented.

A compact, modular PET center which utilizes a cyclotron with the developed

RF generator is proposed. The center is suited for regions with small

population, where one or two PET scanners are needed. The solution allows

to overcome the problem of patients, or vice versa radiopharmaceuticals,

logistics in such regions. The center consists of one or two PET-CT scanners

with the cyclotron and radiopharma production able to produce 55 GBk,

which makes the cyclotron much more compact and cheap than usual PET

cyclotrons. Also such compact cyclotron might be of interest for oncology

clinics which do not have own radiopharma production and suffer from its

logistics issues.

Lecturer biography: G.B. Sharkov

Georgy Sharkov: deputy director of project office, NIITFA (Rosatom). Ph.D.

in physics (ITEP, Moscow). Project manager of solid-state high power RF

amplifiers project (2011-2015, Siemens). Background: relativistic nuclear

physics, particle detectors.


24 N

ov




5.6 CERN MEDICIS AND MEDICIS-PROMED: NOVEL

RADIOISOTOPE PRODUCTION FOR MEDICAL

APPLICATIONS

Corresponding Authors: S. Stegemann

KU Leuven

Institute for Nuclear and Radiation Physics,

Heverlee, Belgium.

MEDICIS-PROMED is a network that bridges different disciplines across

fundamental research institutions, private companies and hospitals for the

production of innovative medical isotopes and radiopharmaceuticals for the

imaging and therapy of cancer. Radioisotopes are commonly used for

functional imaging and are expected to play an enhanced role in treatment of

various types of cancer.

At CERN a new facility is under construction, named MEDICIS, which will

provide dedicated medical batches for radiopharmaceuticals and develop new

accelerator technologies for medical applications. It will extend the

capabilities of the ISOLDE radioactive ion beam facility, operated with a 1.4

GeV proton beam and the on-line mass separator, which allows the

production of a spread variety of radioisotopes for different aims.

MEDICIS-PROMED is a Marie Sklodowska-Curie innovative training

network of the Horizon 2020 European Commission`s program. Outcome of

this network will be a new generation of entrepreneurial scientists, who will

take advantage of the different interdisciplinary fields, in order to develop

medical systems for new personalized medicine and to develop a network of

experts within Europe. The EU support consists of 15 PhD projects based in

different partner sites all over the Europe, which are coordinated by CERN.

MEDICIS-PROMED is a wide project that covers all aspects from the

radioisotope production to the medical application passing through the

collection, shipment, safety control and the radiochemical synthesis. The

project started in April 2015 and will end in 2019. Together with the

completion of the MEDICIS facility (2017), MEDICIS-PROMED will reach

its full speed.

Lecturer biography: S. Stegemann

Simon Segemann is a Marie-Curie Fellow from the Katholieke Universiteit

Leuven, where he is part of the Innovative Marie Sklodowska-Curie Training

Network MEDICIS-PROMED of the Horizon 2020 EU Program. He





24 N

ov

graduated with a master’s degree in physics from the University of Cologne

in April 2016, where he was member of the Bonn-Cologne Graduate School

of Physics and Astronomy Honors Branch (10/2013-04/2016). He is currently

living in Leuven, where he is working as a PhD student on the production of

mass separated 11C beams for PET-aided hadron therapy.


24 N

ov




5.7 MEDICAL IMAGING

Corresponding Authors: J. Llop Roig

CIC BiomaGUNE, Guipuzcoa, Spain.

Radiotracers labeled with positron and gamma emitters can be tracked non-

invasively after administration to a living organism. This is the basics of

nuclear imaging, which has been traditionally used in the clinical setting for

the early diagnose/evaluation of the response to treatment of a variety of

diseases. With the widespread installation of cyclotrons around the world and

the implementation of effective networks for the production and distribution

of radiotracers, nuclear imaging has gained relevance in other fields,

including the pre-clinical and clinical evaluation of new drug candidates and

the investigation of mechanistic aspects of physiological, biological and/or

medical problems.

In this session, the fundamentals of Positron Emission Tomography (PET)

and Single Photon Emission Computerized Tomography (SPECT) will be

briefly introduced. Illustrative examples of the application of nuclear imaging

both in the clinical and the pre-clinical settings will be presented and

discussed.

Lecturer biography: J. Llop Roig

Jordi Llop got his PhD degree in Chemistry in 2002. After post-doctoral

appointments in the radiochemistry laboratory at Navarra University Hospital

(Pamplona, Spain) and Uppsala University PET Centre (Uppsala, Sweden) he

became the Production Manager and Radiochemistry Laboratory Responsible

at Institut d’Alta Tecnologia (Barcelona, Spain). In October 2007, he became

Head of Radiochemistry and Principal Investigator of the Radiochemistry and

Nuclear Imaging Group at CIC biomaGUNE, which are still his current

positions.

His current research interest focuses in the investigation of nanomedicines

using multi-modal imaging, the development of novel strategies for the

preparation of 13N-labelled radiotracers and the design and evaluation of

contrast agents to assess lung ventilation using PET. Dr. Llop has published

over 75 scientific articles, he has co-edited a book, and he has trained 5 PhD

students. Currently he leads 9 researchers (6 PhD students), and he is involved

in different national and international projects related to synthesis and in vivo

investigation of novel radiotracers.




Particle Therapy Session

25 N

ov

6. PARTICLE THERAPY SESSION

6.1 DEVELOPING A MODERN, HIGH-QUALITY PROTON

THERAPY MEDICAL DEVICE USING A COMPACT

SUPERCONDUCTING SYNCHROCYCLOTRON

Corresponding Authors: T. Zwart

MEVION Medical Systems, Littleton, USA

The MEVION S250 is a proton therapy system based on a gantry mounted

superconducting synchrocyclotron. The synchrocyclotron is a 250 MeV

accelerator weighing less than fifteen tons with magnetic fields in excess of

ten Tesla and an extraction radius of only 30 cm. The compact architecture

allows delivery of high quality proton therapy without the need for beam

lines, magnetic gantries or energy selection systems. The entire system is

designed for its intended use as a medical device and is easily operable by a

single therapist without the need for additional engineers or physicists. In

addition to the superconducting magnet, the accelerator includes an efficient

frequency modulated radio frequency system with a slew rate in excess of 50

GHz/sec, maintenance free vacuum and ion source systems and a highly

stable extraction which maintains the proton energy to better than 0.1%. The

fast pulsed nature of a synchrocyclotron is also well suited for efficient and

safe pencil beam scanning delivery. The MEVION S250 Hyperscan system

has of scanning speeds of more than 10 m/sec, layer switching times of less

than 50 ms and volumetric delivery to a one liter field in six seconds resulting

in robust IMPT treatments without the need for patient specific devices.

Lecturer biography: T. Zwart

Townsend Zwart is the Senior Director of Advanced Development at

MEVION Medical Systems. Townsend joined MEVION in 2005 and was

instrumental in the design, development and deployment of the

superconducting synchrocyclotron. He holds several patents in subjects

related to the cyclotron magnet, ion source, extraction optics and beam

scanning systems. Prior to MEVION Townsend was a Research Scientist at

the MIT Bates Accelerator Center where he contributed to the development

of multiple accelerator systems including a 1 GeV electron storage ring and a

polarized electron source.


25 N

ov




Townsend holds a Bachelor of Arts in Physics from Dartmouth College and

a PhD from Boston University in Applied Physics with a concentration in

Accelerator Systems





25 N

ov

6.2 SUPERCONDUCTING MEDICAL ACCELERATORS AT

IBA

Corresponding Authors: W. Kleeven and E. Forton on behalf of

IBA1, AIMA2 and JINR3

1 Ion Beam Applications, B-1348 Louvain

la Neuve, Belgium 2 AIMA, Developpement, Nice, France 3 JINR, Dubna, Moscow Region, Russia

In 2005, IBA started studies and developments of superconducting cyclotrons

for medical applications. In this communication, we will present a summary

of the history and characteristics of the two main superconducting IBA

cyclotrons for particle therapy, namely the Cyclone 400 for proton/carbon

therapy and the S2C2 dedicated to proton therapy, with a particular emphasis

on their superconducting coil systems.

In the conclusions, we will discuss how IBA sees a trend in the use of

superconductivity in therapy equipment.

Lecturer biography: W. Kleeven

Wiel Kleeven did his PhD study at the Eindhoven University of Technology

(EUT) on the theory of accelerated orbits, including space charge issues in

cyclotrons. He then moved to Triumf for a postdoc position before returning

to EUT, where he was also appointed post-doc researcher.

Since then, Wiel Kleeven is now for more than 20 years involved in the R&D

activities of IBA. He developed in-house accelerator computing capabilities

and participated in every major design, commissioning and improvements of

medical and industrial accelerators in IBA’s portfolio.

He is now still working as senior accelerator Physicist and honorary fellow at

IBA, which allows him to also pursue collaborations and research of broader

interests.


25 N

ov




6.3 SUPERCONDUCTING MAGNETS FOR ULTRA-LIGHT

AND MAGNETICALLY SHIELDED, COMPACT

CYCLOTRONS FOR MEDICAL APPLICATIONS

Corresponding Authors: J.V. Minervini, A. Radovinsky, P. Michael,

L. Bromerg

Massachusetts Institute of Technology

Plasma Science and Fusion Center, Cambridge,

USA

Superconducting cyclotrons are increasingly employed for proton beam

radiotherapy treatment (PBRT). The use of superconductivity in a cyclotron

design can reduce its mass an order of magnitude, yielding significant

reduction in overall cost of the device, the accelerator vault and its

infrastructure, as well as operating costs. Despite several decades of design

effort, the magnetic configuration for superconducting cyclotrons remains

relatively unchanged from that proposed by Lawrence over 80 years ago for

resistive-magnet-based cyclotrons. The basic configuration still consists of a

single, split pair solenoid embedded in a relatively massive iron return yoke,

with the radial magnetic field profile in the acceleration region produced by a

pair of magnetically saturated iron poles. The use of a warm iron yoke also

requires the transmission of substantial electromagnetic loads across the

cryostat boundary; these loads must be accommodated in the cryogenic

design of the magnet vessel.

At MIT, we previously developed a design for a very high field

superconducting synchrocyclotron (9 T at the pole face) that results in a

compact device that is small enough and light enough to mount directly on

the beam delivery gantry, entirely eliminating the beam delivery system. As

a next step for advancing superconducting cyclotron technology we are

developing a method to design a compact superconducting synchrocyclotron

that demonstrates the possibility to reduce its weight significantly by

eliminating all iron from the design. Implementation of this proposed design

benefits from several significant advances in superconducting magnet

technology pioneered in the magnetic resonance imaging (MRI) industry

during the past 20 years, such as active magnetic shielding.

In addition to the prospect of reduced weight, smaller accelerator vault

volume, enhanced magnetic shielding, and structural efficiency, the linear

relationship between operating current and field magnitude facilitates the

development of iron-free synchrocyclotrons with the capability for beam

energy variation without a degrader. Reliance on an energy degrader comes





25 N

ov

at the cost of undesirable production of secondary radiation that markedly

increases the amount of radiation shielding required. Simultaneous with this

beam energy degradation is another negative consequence, reduction of the

beam current. Additionally this concept could potentially be used for

acceleration of a variety of ion species in a single device.

Lecturer biography: J. V. Minervini

Joseph Minervini is Assistant Director of the Plasma Science and Fusion

Center (PSFC) at MIT. He also is Division Head for Technology and

Engineering, and holds an academic appointment as Senior Research

Engineer in the Nuclear Science and Engineering Department where he

teaches a course and supervises graduate student research. His present duties

include spokesperson for the U.S. Magnetics Program organized under the

Office of Fusion Energy Science (OFES) in the Department of Energy.

Dr. Minervini has played a leading role in the field of large-scale applications

of superconductors for more than 30 years. He has worked on magnet systems

covering nearly every major application of large-scale superconductivity

including fusion energy, magnetic levitation, energy storage, power

generation and transmission, magnetic separation, high energy and nuclear

physics, as well as medical applications. Among his recent research interests

is the development of very high-field, highly compact cyclotron accelerators

for medical applications (proton and carbon radiotherapy, PET isotope

production), for security applications (detection of strategic nuclear

materials), and for laboratory research in nuclear physics. Another major

research focus is the application of High Temperature Superconducting

materials for advanced, compact fusion devices, and forincreasing power grid

efficiency and efficiency of data centers.

Dr. Minervini holds a B.S. Engineering degree from the U.S. Merchant

Marine Academy, Kings Point, and the S.M. and Ph.D. degrees in Mechanical

Engineering from the Massachusetts Institute of Technology.


25 N

ov




6.4 MODERN INJECTOR LINAC CONCEPTS FOR

HADRONTHERAPY

Corresponding Authors: B. Schlitt

Helmholtzzentrum für Schwerionenforschung,

GSI, Darmstadt, Germany

Several clinical synchrotron facilities for carbon ion-beam therapy were

constructed worldwide during the last decade. State-of-the-art at these

facilities is a compact room-temperature injector linac operated at about 200

MHz and comprising at least one electron cyclotron resonance (ECR) ion

source, a radio-frequency quadrupole linac (RFQ), and an Interdigital H-

mode drift tube linac (IH-DTL). Whereas superconducting linacs are

favorable for high-duty cycle or cw operation, room-temperature linacs still

have advantages for low-duty cycle machines like synchrotron injectors.

Recent developments applying higher frequencies and higher gradients as

well as more compact RF supplies based on solid state power amplifiers or

IOTs may open new options for future injectors. An overview of present

injector linacs as well as selected recent developments will be presented.

Lecturer biography: B. Schlitt

Since 1993 accelerator physicist at GSI Darmstadt, Germany, accelerator

operations division; currently deputy head of the Linac RF department and in

charge of the modernisation of the RF systems at the Alvarez section of the

GSI heavy-ion linac UNILAC

PhD in Physics in 1997 from Heidelberg University, Germany (Schottky mass

spectrometry at the heavy ion storage ring ESR at GSI)

1997 – 2010 development, construction, and commissioning of the 7 MeV/ u,

217 MHz carbon ion injector linacs for heavy-ion beam therapy centers





25 N

ov

6.5 SUPERCONDUCTIVITY IN CYCLINACS FOR ION BEAM

THERAPY

Corresponding Authors: A. Garonna, U. Amaldi, E. Felcini

TERA Foundation, Novara, Italy

Cyclinacs are accelerators, which combine the two leading technologies in

the medical field: a cyclotron injector (the workhorse accelerator in proton

therapy and radiopharmacy) and a linac booster (the accelerator type used in

every medium-sized hospital for radiotherapy and radioimaging). The linac

technology offers the unique potential to increase the performance of

accelerators for ion beam therapy, through the fast energy modulation and

small transverse size of its high repetition rate pulsed beam. This allows to

bring accelerators one step forward towards image guided ion beam therapy

and thus, to increase the quality of beam delivery for the treatment of moving

organs.

The superconducting technology plays here an essential role. Indeed, the most

cost-effective solutions for cyclinacs make use of superconducting cyclotron

injectors. Conceptual designs of such cyclotrons will be presented. In

addition, using superconducting combined-function magnets (FFAG) in the

beam delivery lines and gantries would allow to make the best use of the fast

beam energy modulation of the linac while keeping beamline (i.e. facility)

dimensions as compact as possible.

Lecturer biography: A. Garonna

Adriano Garonna obtained in 2011 his PhD from the Swiss Federal Institute

of Technology in Lausanne on the design of cyclotrons for ion beam therapy.

He subsequently designed a slow extraction system for the Bio-LEIR project

as a post-doctoral fellow at CERN and led the accelerator commissioning for

proton treatments at the MedAustron ion beam therapy centre. Adriano is

presently Technical Director at TERA, an Italian research foundation with

offices at CERN.


25 N

ov



Gantries Session

7. GANTRIES SESSION

7.1 INTRODUCTION TO GANTRIES AND COMPARISON OF

GANTRY DESIGN

Corresponding Authors: M. Pullia1, F. Ebskamp2

1Centro Nazionale di Adrontetapia Oncologica,

CNAO, Pavia, Italy 2Danfysik, Taastrup, Denmark

This presentation reviews the state of the art of gantry designs and

technologies. Gantries for proton particle therapy are currently installed

worldwide, and there is a similar wish to use gantries for particle therapy

using hadrons, such as carbon and helium. Only few carbon gantries have

been built, based on normal-conducting magnets as well as superconducting

magnet technology. Several other design concepts have been proposed, such

as the Riesenrad design. A comparison of gantry designs will be presented,

including investment cost and operational aspects.

Lecturer biography: M. Pullia

Marco Pullia got his degree in physics at the Università degli Studi of Milano

(Italy) and his PhD at the UCBL in Lyon (France). He has been working in

the domain of accelerators for hadrontherapy since 1993 when he was hired

by TERA and he is with CNAO since 2003. Marco Pullia was in charge of

the accelerator during the CNAO construction is now leading the accelerator

R&D at CNAO.

Lecturer biography: F. Ebskamp

Frank Ebskamp, has a M.Sc. degree from Leiden University in the

Netherlands, and a Ph.D. degree from Danish Technical University in

Denmark. He has held several management positions in engineering

companies for the last two decades, and has been CEO for Danfysik since

2014. Danfysik provides particle accelerator technology to industry,

healthcare and research facilities.




Gantries Session

25 N

ov

7.2 ADVANTAGES AND CHALLENGES OF SC MAGNETS IN

GANTRIES

Corresponding Authors: A. Gerbershagen

Paul Scherrer Institut, Villen, Switzerland.

The presentation provides an overview of the current developments in

superconducting magnets for applications in proton and ion therapy gantries.

It summarizes the benefits and challenges regarding the utilization of these

magnets from the economical, infrastructural and technical points of view.

The options for the superconducting material choice, magnet geometry,

cooling system and beam optics design are stated and their individual features

are reviewed. The challenges of fast magnet ramping and large stray fields of

the ironless magnets are presented and the possibilities to solve these

challenges are suggested. Also, the examples of currently used

superconducting particle therapy systems and proposed designs are provided.

The technical benefits and risks of these designs are discussed and the

potential new treatment and patient diagnostic options are mentioned.

Lecturer biography: A. Gerbershagen

Alexander Gerbershagen has a master’s degree in mathematical physics from

University of Cambridge and a doctorate in particle physics from the

University of Oxford, UK. He has worked at CERN on the beamline design

of a future electron-positron collider CLIC and now works at Paul Scherrer

Institute (PSI) as an accelerator physicist. His responsibilities include the

maintenance of the PSI proton therapy facility PROSCAN as well as R&D on

its upgrades. In particular, he investigates the potential use of the

superconducting magnets in future gantries.


25 N

ov



Gantries Session

7.3 SUPERCONDUCTING MAGNETS FOR MEDICAL

APPLICATIONS AT PSI

Corresponding Authors: C. Calzolaio, S. Sanfilippo

Paul Scherrer Institut, Villen, Switzerland.

The use of proton therapy for cancer treatment shows a growing trend, since

the radiation dose delivered to the target volume is maximized and the dose

to the surrounding healthy tissues is minimized. To direct the proton beam

from all directions to the tumor in the patient, the last part of the beam

transport and scanning system are mounted on a rotatable gantry.

In this work a design of a superconducting bending magnet section for future

compact iso-centric gantries is presented. The section consists of three

combined function magnets: two dipole, quadrupole and sextupole magnets

and a combined quadrupole and sextupole magnet. All the winding packs are

based on racetrack coils to keep the manufacturing as easy as possible.

The coils will be wound with Nb3Sn Rutherford cables. Following the choice

of a suitable superconducting strand, we report the calculation of the AC

losses during the energy sweeps, the expected temperature margin both during

a transient and in steady state and the design of the cooling system as well as

of the mechanical support structure. Some considerations about the quench

protection scheme are also presented.

Lecturer biography: C. Calzolaio

Ciro Calzolaio studied Nuclear Engineering at the University of Bologna.

After that He got a PhD in pysics at the École polytechnique fédérale de

Lausanne (EPFL) working on the irreversible degradation in Nb3Sn Cable in

Conduit Conductors for the ITER project. After the PhD He worked at the

University of Geneva on the electromechanical characterization of Nb3Sn

strands. Since 2015 He work in the magnet group at Paul Scherrer Institute

(PSI). My main topics concern the development of superconducting magnets

for the next generation of proton therapy facilities at PSI and the upgrade of

the Swiss Light Source.




Gantries Session

25 N

ov

7.4 SC GANTRY AT NIRS AND NEW DEVELOPMENTS IN

SC MAGNETS FOR GANTRIES & SYNCHROTRONS

Corresponding Authors: Y. Iwata

National Institute of Radiological Sciences, NIRS

Department of Accelerator and Medical Physics,

Chiba, Japan

A superconducting (SC) rotating-gantry for carbon radiotherapy was

developed. This isocentric rotating gantry can transport carbon ions with the

maximum energy of 430 MeV/u to an isocenter with irradiation angles of over

+-180 degrees, and is further capable of performing three-dimensional raster-

scanning irradiation. The combined-function SC magnets were employed for

the rotating gantry. The SC magnets with optimized beam optics allowed a

compact gantry design with a large scan size at the isocenter; the length and

the radius of the gantry are approximately 13 and 5.5 m, respectively, which

are comparable to those for the existing proton gantries. The total weight of

the gantry is estimated to be approximately 300 tons. Construction as well as

installation of the SC gantry was completed by the end of September, 2015.

Beam commissioning subsequently begun since October, 2015, and carbon

beams, as accelerated by the HIMAC upper synchrotron, having kinetic

energy of between 430-48 MeV/u were successfully transported with the SC

gantry to the isocenter. Presently, we are further designing a next-generation

compact SC gantry as well as a SC synchrotron as a future project. In this

talk, the recent progress of the SC rotating-gantry as well as new

developments for the future project is presented.

Lecturer biography: Y. Iwata

2000: Ph.D in Physics (Experimental nuclear physics)

~2006: Developments of a compact injector

~2011: Developments of the accelerator control system of HIMAC

accelerators for multiple-flattop operation

~Present: Developments of a superconducting rotating-gantry


25 N

ov



Gantries Session

7.5 CRYOGENIC DESIGN AND COLLING METHODS FOR

ROTATING SC MAGNETS

Corresponding Authors: B. Baudouy

French Alternative Energies and Atomic Energy

Commision, CEA

Accelerators, Cryogenics and Magnetism

Division, Saclay, France

The cryogenic design of rotating superconducting magnet, especially for

particle therapy, is governed not only by the operating conditions but also by

end-user’s environment. These specific design considerations, presented as

an introduction, narrow down the different possible cryogenic cooling options

for such superconducting systems. In light of these considerations, the gantry

system design studied at CEA Saclay will be discussed and the chosen

“cryocooling” method evaluated. A focus on thermal links for cryocooling,

with a particular emphasis on the conductive thermal links, will be presented

where the pros and cons will be assessed. Based on this assessment, we

propose an alternative two-phase cryogen thermal links: the pulsating heat

pipe and discuss their thermal performance and advantages. To conclude, the

recent developments of pulsating heat pipe thermal links under development

at CEA Saclay will be presented.

Lecturer biography: B. Baudouy

Dr. Bertrand Baudouy received his PhD in fluid mechanics from the Pierre

and Marie Curie University (University of Paris VI) in Paris in 1996 for the

study on heat and mass transfer in superfluid helium in superconducting

magnets. He received his research habilitation (H.D.R.) in 2015 from the

department of physics of the University Paris-Sud (University of Paris XI).

His research activities, primarily experimental, concern the low temperature

heat and mass transfer related to the cooling techniques of superconducting

magnets or other cryo-magnetic systems. Currently, his work focuses on heat

transfer and fluid dynamics of liquid helium from superfluid to normal two-

phase regime as well as other cryogens. He is involved in the study of natural

circulation loop using different cryogens, heat and mass transfer in confined

geometry (micro-channels and porous media), numerical modeling of

superfluid helium heat transfer and the development of two-phase heat pipes

technology, like pulsating heat pipes. He is the European editor of the

Elsevier international journal Cryogenics since 2012.




Gantries Session

25 N

ov

7.6 CRYOGEN FREE CRYOGENIC COOLING SYSTEM FOR

ROTATING SUPERCONDUCTING MAGNETS IN

MEDICAL ACCELERATORS

Corresponding Authors: S. Sanz, G. Sarmiento, J.M: Merino, A.

Pujana, I. Marino, L. Emaldi1, J. Sun,

R. Müller, H. Neumann2

1 TECNALIA, Derio, Spain 2 Karlsruhe Institute of Technology, KIT

Institute for Technical Physics (ITEP),

Eggenstein-Leopoldshafen, Germany

Large rotating magnets are essential components in hadron therapy facilities,

with both proton and carbon ions. In the so called gantries, the beam is rotated

and bent pointing through the patient tissues. This is achieved usually by

tilting or rotating the complete and weighty magnet system. Present trends are

directing to more compact and less power consuming gantries using

superconducting magnets, where rotating cryogenic cooling system is

required.

Under the EU Seventh Framework Programme, the SUPRAPOWER project

pursues a 10 MW superconducting generator for wind turbines. In this project,

a cryogen-free cryogenic cooling system for the generator rotor coils based

on Gifford-McMahon cryocooler has been designed and validated

experimentally. In this frame, a rotary joint has also been developed in order

to connect the rotating cold head to the stationary helium compressor. Based

on the cooling system developed for the superconducting generator, a similar

cryogen-free design is outlined for superconducting gantries. Implementation

of such rotary joints would offer a new solution for gantries with an

unbounded rotation of 360º.

Lecturer biography: S. Sanz

Santiago Sanz Castillo was born in 1977. He received his PhD degree from

the University of the Basque Country, Bilbao, Spain, in 2013, with a thesis

dedicated to the design, construction and testing of HTS coils for energy

applications. He currently works as researcher in the fields of cryogenics and

superconductivity in Tecnalia, Derio, Spain (since 2012). Before this, he has

been trained in institutions such as Ciemat and in companies such as Airbus

and Arcelor-Mittal. Over the last twelve years, he has been involved in the


25 N

ov



Gantries Session

development of superconducting devices, both HTS and LTS, for several

applications such as particle accelerators, wind energy and fusion.




Sponsors S

pon

sors

8. SPONSORS

TESLA Engieering Ltd. is dedicated to the design,

manufacture and support of resistive and

superconducting electromagnets, gradient coils,

composite materials, generator coils, motors and

consultancy to science, medicine and industrial

markets.

TESLA Engineering Ltd. in the UK consists of

a Magnet Division and a Gradient Division which

design and manufacture magnets including bending

and focusing magnets for particle accelerators

specialized gradient coils for use in MRI systems

and advanced superconducting magnets for

emerging markets such as nuclear fusion, renewable

energy sources, semi-conductor processing and

cancer therapy.

Danfysik provides high performance particle

accelerators and related equipment for research,

health care and industry globally. Power supplies,

magnets, insertion devices,beam diagnostics,

electrostatic devices, others....

Today Danfysik has grown to be a state of the art

manufacturer of advanced technology components

and complete systems of high quality for the

synchrotron radiation and particle accelerator

markets.

Elytt Energy is an innovative company, working in

high technology projects, developing and

manufacturing equipment for particle accelerators

for scientific research and medical usage.

Elytt Energy offers complete Resistive and

superconducting eletromagnets for accelerators,

power supplies, flyweels, kinetic energy storage,

engineering...

http://www.ciemat.es/

http://www.ciemat.es/

http://www.tesla.co.uk/magnet/

http://www.tesla.co.uk/gradient/

http://www.danfysik.com/

http://www.danfysik.com/en/products/power-supplies/

http://www.danfysik.com/en/products/magnets/

http://www.danfysik.com/en/products/insertion-devices/

http://www.danfysik.com/en/products/beam-diagnostics/

http://www.danfysik.com/en/products/electrostatic-devices/

http://www.danfysik.com/en/products/other/

http://www.elytt.com/

http://www.elytt.com/#!modules/pages/content/25







Sp

on

sors



Sponsors

Jema IRIZAR GROUP designs and manufactures

Static Power Converters for different sectors as

Plasma physics, particle accelerators, MRI and

renewable energy.

Jema IRIZAR Group are customer orientated,

developing bespoke systems and solutions which

meet specific requirements of each project. Over 20

years, JEMA has developed several custom power

supplies for most of the experimental fusion

reactors in Europa, (MAST, JET, W7X, TJ-II, TCV,

etc...)

IBA (Ion Beam Applications S.A.) is a global

medical technology company focused on bringing

integrated and innovative solutions for the

diagnosis and treatment of cancer. IBA's proton

therapy solutions are flexible and adaptable,

allowing customers to choose from universal full-

scale proton therapy centers as well as compact

single room solutions. In addition, IBA also has a

radiation dosimetry and radio-pharmacies business

and develops particle accelerators for the

medical world and industry.

With Proteus system, developed in collaboration

with top clinical institutions, IBA is the first

company to introduce Pencil Beam Scanning, in-

room CT, Cone Beam CT or Prompt Gamma

Camera for clinical use in proton therapy.

With Cyclone systems, IBA offers packages to

manufacture radioparmaceuticals for nuclear

medicine.

http://www.jemaenergy.com/en/

https://iba-worldwide.com/

http://iba-worldwide.com/proton-therapy

http://iba-worldwide.com/proton-therapy

http://www.iba-dosimetry.com/

http://www.iba-radiopharmasolutions.com/

http://www.iba-industrial.com/

https://iba-worldwide.com/proton-therapy

http://www.iba-radiopharmasolutions.com/products/cyclotrons#cyclone-kiube




Sponsors S

pon

sors

Varian medical systems have pioneered

developments in the fields of radiotherapy,

oncology, X-ray tube technology, digital image

detectors, cargo screening, and non-destructive

testing. They have a robust portfolio, and long-

standing relationships with many of the world's

leading clinicians and manufactures of industrial

and medical imaging systems.

Varian's ProBeam system is at the forefront of the

industry, having created the world´s first

commercially available system. This is able to

deliver intensity-modulated proton therapy (IMPT),

which is recognized for its effectiveness and

conformity of dose delivery.

Sedecal, Sociedad Española de Electromedicina y

Calidad S.A, was founded on January 1994 with

completely Spanish equity. During this time, they

have had a continuous growth that has positioned as

worldwide leaders in OEM design and

manufacturing of high frequency X-Ray generators

and X-Ray systems.

Sedecal has six divisions leading their field

expertise: OEM Division, medical radiology; Pre-

clinical Division, PET and PET/CT; Veterinary

Division, veterinary radiology; Healthcare

Division, medical ozone generation; Industrial

Division, industrial power control and renewable

energies; Industrial Subcontracting Division,

printed circuits boards, electronic systems and

eletromechanical systems.

https://www.varian.com/es

https://www.varian.com/es/oncology/products/treatment-delivery/probeam-proton-therapy-system

https://www.varian.com/es/oncology/products

https://www.varian.com/es/x-ray-imaging-components/products

https://www.varian.com/oncology/products/treatment-delivery/probeam-proton-therapy-system

http://www.sedecal.com/sedecal.com/en/home/index.php?i=2

http://www.sedecal.com/sedecal.com/en/divisiones/division.php?c=1&i=2











Sp

on

sors



Sponsors




Notes

Notes


Note

s



Notes

Documents

Final program and Abstracts€¦ · Page 4 CIEMAT 24-25 November 2016 -Industry matching event on superconductivity for ContentsAcademia accelerators for medical applications